Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 6/20 | 0.63 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023750 | 0.88 | LCK (0.60) | LCKPI4KBALDH1A1CA1CA2 | |
| SCHEMBL24735699 | 0.88 | LCK (0.63) | LCKALDH1A1TSHRNPC1 | |
| SCHEMBL539568 | 0.87 | LCK (0.62) | LCKPKMALDH1A1TSHRHPGD | |
| SCHEMBL773470 | 0.84 | LCK (0.66) | LCKPI4KBALDH1A1CA1CA2 | |
| SCHEMBL4605012 | 0.84 | ALDH1A1 (0.69) | LCKALDH1A1HPGDNPC1 | |
| SCHEMBL8553256 | 0.84 | LCK (0.59) | LCKPKMTDP1ALDH1A1TSHR | |
| SCHEMBL16753973 | 0.84 | LCK (0.53) | LCKPI4KBCA1CA2 | |
| SCHEMBL12056453 | 0.84 | LCK (0.53) | LCKPI4KBCA1CA2 | |
| SCHEMBL31661292 | 0.83 | LCK (0.59) | LCKPI4KBALDH1A1CA1CA2 | |
| SCHEMBL24735744 | 0.83 | LCK (0.58) | LCKPI4KBALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034105-A1 | Generative AI-Assisted Identification of Novel PI3K-alpha Inhibitors | THE FIRST AFFILIATED HOSPITAL OF XI'AN JIAOTONG UNIVERSITY (CN) | 2026-02-05 | — | — | US | disclosed |
| US-11793885-B2 | Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders | IMMUNOGEN, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20200397914-A1 | BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2020-12-24 | — | — | US | disclosed |
| CN-107001339-A | Novel compounds | 特殊治疗有限公司 | 2017-08-01 | — | — | CN | disclosed |
| EP-2948442-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-9175003-B2 | Substituted azoanthracene derivatives and intermediates for preparation thereof | VTV THERAPEUTICS LLC (US) | 2015-11-03 | — | — | US | disclosed |
| US-9133204-B2 | 5-membered heterocyclic amides and related compounds | H. LUNDBECK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| EP-2413693-B1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2178865-B1 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | LUNDBECK H AS (DK) | 2015-08-19 | — | — | EP | disclosed |
| CN-104844578-A | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | NEUROGEN CORP | 2015-08-19 | — | — | CN | disclosed |
| EP-2029138-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-04 | — | — | EP | disclosed |
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| CN-101296911-A | Arylurea derivatives as modulators of chemokine receptor activity | NOVARTIS AG (CH) | 2008-10-29 | — | — | CN | disclosed |
| EP-1943235-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Novartis AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| CN-101208089-A | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC (CA) | 2008-06-25 | — | — | CN | disclosed |
| EP-1525193-B1 | ACYLAMINOTHIAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007130075-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | disclosed |
| EP-1758564-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | Brystol-Myers Squibb Company (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005094376-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR4 | LCK 2046/4885PI4KB 2097/4885PKM 4217/4885 |
| US-20260034105-A1 | Generative AI-Assisted Identification of Novel PI3K-alpha Inhibitors | PIK3R1, PIK3R4, PIK3R2 | LCK 1544/4885PI4KB 7/4885PKM 3062/4885 |
| US-20200397914-A1 | BENZODIAZEPINE DERIVATIVES | GABRA5, GABRA3, GABRA1 | LCK 4291/4885PI4KB 3871/4885PKM 1134/4885 |
| US-11793885-B2 | Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders | MKI67, GABBR1, GABBR2 | LCK 3733/4885PI4KB 3134/4885PKM 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.